Snapshot · FTSE 250 · generated 2026-10-13 03:44 UTC

HIK.L — Hikma Pharmaceuticals PLC

UNDERVALUED (MOS +28.6%) · Quality 63/100

HIK.L - Hikma Pharmaceuticals PLC
Data generated 2026-10-13 03:44 UTC (nightly scan, universe: FTSE 250).
Price: 16.12 USD
Intrinsic value: 22.56 USD
Margin of safety: +28.6%
Implied growth (reverse DCF): +3.1% (model assumes +8.6%)
Valuation: UNDERVALUED
Value Score: 37.1
Quality: 63/100
Moat score: 53.8 (erosion: none)
UNDERVALUED (MOS +28.6%) - Quality 63/100
Source: StocksDeepDive - https://stocksdeepdive.com/s/HIK.L
Factual information and general commentary only. StocksDeepDive publishes data, model outputs and described calculations from stated inputs. Nothing on this site takes your personal objectives, financial situation or needs into account, and nothing here is financial product advice or a recommendation to buy, hold or sell any security. Model outputs depend entirely on their stated inputs and assumptions. Consider seeking advice from a licensed adviser before acting. Data via Yahoo Finance, Google Trends, StockTwits and NewsAPI; figures may be delayed or revised.

Price

16.12

Intrinsic value

22.56

Margin of safety

+28.6%

Implied growth (reverse DCF)

+3.1%

model assumes +8.6%

Value Score

37.1

Quality

Psychology

2.5

Discovery

4.2

price/volume attention only

Moat score

53.8

erosion: none

Value Score: top 36% of FTSE 250 · Quality: top 36%

Dividend: 0.6438/share (TTM) · yield 4.0% · payout 45%

Open the interactive Deep Dive for HIK.L →

Use this data programmatically

This page's numbers are also available as JSON at /api/v1/deep-dive/HIK.L - see the API docs for the full read-only surface, including an MCP server for AI assistants.

Common questions

Is HIK.L undervalued?

As of 2026-10-13, HIK.L trades at 16.12 against a computed intrinsic value of 22.56 (+28.6% margin of safety) - StocksDeepDive's valuation label for this is UNDERVALUED. This is a described calculation from public data, not a recommendation.

What is Hikma Pharmaceuticals PLC's Value Score?

Hikma Pharmaceuticals PLC's Value Score is 37.1 as of 2026-10-13 - it combines value, quality, crowd psychology and market attention into one number.

Does HIK.L pay a dividend?

Yes - HIK.L's trailing twelve-month dividend is 0.6438/share, a yield of 4.0% at the current price (as of 2026-10-13).